At a glance
- SLU-PP-332 is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 10 publications mentioning it, including 0 randomized controlled trials and 3 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.
- Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.